Identification and validation of key genes with prognostic value in non ‐small‐cell lung cancer via integrated bioinformatics analysis
ConclusionThe results showed thatAURKA,KIAA0101,CDC20,MKI67,CHEK1,HJURP, andOIP5 may be critical genes in the development and prognosis of NSCLC.Key pointsOur results indicated thatAURKA,KIAA0101,CDC20,MKI67,CHEK1,HJURP, andOIP5 may be critical genes in the development and prognosis of NSCLC. Our methods showed a new way to explore the key genes in cancer development. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 15, 2020 Category: Cancer & Oncology Authors: Li Wang, Jialin Qu, Yu Liang, Deze Zhao, Faisal UL Rehman, Kang Qin, Xiaochun Zhang Tags: ORIGINAL ARTICLE Source Type: research

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non ‐small cell lung cancer prior to the approval of durvalumab
ConclusionsPrior to the approval of durvalumab, the clinical application of ICIs improved the outcome of patients with relapsed NSCLC after CRT for LA ‐NSCLC. The management of radiation pneumonitis remains a challenge following the approval of durvalumab. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 15, 2020 Category: Cancer & Oncology Authors: Tomoya Fukui, Shinji Hosotani, Itaru Soda, Takahiro Ozawa, Seiichiro Kusuhara, Mikiko I. Kakegawa, Masashi Kasajima, Yasuhiro Hiyoshi, Satoshi Igawa, Masanori Yokoba, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Hiromi Tags: ORIGINAL ARTICLE Source Type: research

Review: The role of IL ‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
This article reviews the biochemical mechanism, function and genotype of IL‐6, and summariz es the diagnostic and prognostic value of IL‐6 level. Anti‐IL‐6 therapy does not affect the effect of immunocheckpoint inhibitors (ICIs), but enhances its anticancer function, which may be the treatment option for immune‐related adverse events (irAEs) in the future. Therefore, IL‐6 may be a therapeutic target for the treatment of NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 13, 2020 Category: Cancer & Oncology Authors: Wanhai Ke, Li Zhang, Yan Dai Tags: MINI REVIEW Source Type: research

Clinical diagnosis and treatment of immune checkpoint inhibitors ‐related endocrine dysfunction
As a new class of antitumor drugs, immune checkpoint inhibitors (ICIs) have shown remarkable efficacy toward the treatment of various malignant tumors. By virtue of their targets and mechanisms of action, ICIs can cause autoimmune and inflammatory effects, termed as immune ‐related adverse events (irAEs) and unlike the adverse reactions of traditional therapies, irAEs are occult and not fixed, with some serious adverse reactions forcing patients to stop treatment which might even affect their survival. Therefore, with the wide clinical application of ICIs, clinician s need to fully understand the possible adverse reactio...
Source: Thoracic Cancer - February 13, 2020 Category: Cancer & Oncology Authors: Lian Duan, Linjie Wang, Hanping Wang, Xiaoyan Si, Li Zhang, Xiaowei Liu, Yue Li, Xiaoxiao Guo, Jiaxin Zhou, Huijuan Zhu, Li Zhang Tags: CLINICAL GUIDELINE Source Type: research

Long ‐term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report
Pulmonary pleomorphic carcinoma (PPC) is a non ‐small‐cell lung cancer, resistant to chemotherapy and no standard therapy has as yet been established. We herein report the case of a 59‐year‐old man with PPC who showed a long‐term response with durvalumab after chemoradiotherapy. He was referred to our hospital with a mass shadow at the right upper lung. PPC clinical stage IIIB was diagnosed, and the tumor proportion score of programmed death‐ligand 1 (PD‐L1) was 100%. Six days after transbronchial biopsy, he had difficulty walking owing to sensory abnormalities. We found that the primary tumor had invaded the...
Source: Thoracic Cancer - February 13, 2020 Category: Cancer & Oncology Authors: Takafumi Yorozuya, Tetsuya Taya, Kento Yasuda, Yutaro Nagano, Makoto Shioya, Hirofumi Chiba, Hiroki Takahashi Tags: CASE REPORT Source Type: research

Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm
This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non ‐small cell lung cancer (NSCLC).MethodsMedical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in disease ‐free survival (DFS) and DFS‐associated factors between patients receiving lobectomy and surgeons' preference sublobar resection were analyzed after 1‐1 propensity score‐matching (n = 119 per group).ResultsIn total, 1064 pathological stage I NSCLC patients were identified, including 816 (76.7%) who underw...
Source: Thoracic Cancer - February 11, 2020 Category: Cancer & Oncology Authors: Chien ‐Sheng Huang, Po‐Kuei Hsu, Chun‐Ku Chen, Yi‐Chen Yeh, Han‐Shui Hsu, Chun‐Che Shih, Biing‐Shiun Huang Tags: ORIGINAL ARTICLE Source Type: research

Utility of CT radiomics for prediction of PD ‐L1 expression in advanced lung adenocarcinomas
ConclusionsQuantitative CT radiomic features can predict PD ‐L1 expression in advanced stage lung adenocarcinoma. A prediction model composed of clinical variables and CT radiomic features may facilitate noninvasive assessment of PD‐L1 expression.Key pointsSignificant findings of the studyQuantitative CT radiomic features can help predict PD ‐L1 expression, whereas none of the qualitative imaging findings is associated with PD‐L1 positivity.What this study addsA prediction model composed of clinical variables and CT radiomic features may facilitate noninvasive assessment of PD ‐L1 expression. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 11, 2020 Category: Cancer & Oncology Authors: Jiyoung Yoon, Young Joo Suh, Kyunghwa Han, Hyoun Cho, Hye ‐Jeong Lee, Jin Hur, Byoung Wook Choi Tags: Original Article Source Type: research

A novel conservative treatment to reduce cardiac herniation following intrapericardial pneumonectomy
Thoracic Cancer, EarlyView. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 9, 2020 Category: Cancer & Oncology Authors: Yunping Lan, Bin Hu, Xiaozun Yang, Bo Tian, Xiaojun Yang, Qiang Li, Ting Wang, Qinghua Zhou, Yunxia Zuo Tags: IMAGING IN THORACIC CANCER Source Type: research

Metformin alleviates breast cancer through targeting high ‐mobility group AT‐hook 2
ConclusionMetformin resists the growth of breast cancer through targeting Sp1/HMGA2 signal. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 7, 2020 Category: Cancer & Oncology Authors: Yang Li, Dan Wang, Hui Ren, Wei Feng Tags: ORIGINAL ARTICLE Source Type: research

Nm23 ‐H1 inhibits lung cancer bone‐specific metastasis by upregulating miR‐660‐5p targeted SMARCA5
ConclusionNm23 ‐H1 inhibits tumor progression and bone‐specific metastasis of lung cancer by regulating miR‐660‐5p/SMARCA5/RANKL axis, which indicates the related genes may serve as potential targets for the treatment of human lung cancer.Key pointsSignificant findings of the studyHigh expression of nm23 ‐H1 correlated with decreased miRNA‐660‐5p expression. Further, downregulation of miR‐660‐5p significantly suppressed the tumor progression and bone‐specific metastasis of lung cancer cells.What this study addsThis is the first study to show an inverse association between nm23 ‐H1 and miR‐660‐5p, ...
Source: Thoracic Cancer - February 6, 2020 Category: Cancer & Oncology Authors: Cheng Ai, Guangzhi Ma, Yunfu Deng, Qiangqiang Zheng, Yingcai Gen, Wen Li, Yang Li, Lingling Zu, Qinghua Zhou Tags: ORIGINAL ARTICLE Source Type: research

S ‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501
Thymic carcinoma is a rare epithelial tumor of the thymus with a poor prognosis, and multimodal approaches are important for its treatment. Recently, a number of studies have indicated that S ‐1 treatment is effective against thymic carcinoma. S‐1 plus cisplatin with concurrent radiotherapy is a commonly used treatment for other malignancies, including non‐small cell lung cancer (NSCLC). In addition, its safety has been confirmed, and it has been reported to have a marked effect ag ainst thymic carcinoma. Therefore, we conducted a phase II study of S‐1 plus cisplatin with concurrent thoracic radiotherapy for locall...
Source: Thoracic Cancer - February 5, 2020 Category: Cancer & Oncology Authors: Minoru Fukuda, Soichiro Funaki, Takuya Yamazaki, Shuntaro Sato, Hiroshi Mukae, Mitsuhiro Takenoyama, Junya Fukuoka, Kazuki Nabeshima, Hisashi Tateyama, Kazuto Ashizawa, Masaki Hara, Takashi Seto, Meinoshin Okumura, Kenji Sugio Tags: ORIGINAL ARTICLE Source Type: research

Pegylated recombinant human granulocyte colony ‐stimulating factor regulates the immune status of patients with small cell lung cancer
ConclusionsPEG ‐rhG‐CSF regulates the immune status of SCLC patients; CD4+ T cells may be the main effector cells involved in this process. These findings may optimize the treatment of SCLC.Key points PEG ‐rhG‐CSF regulates SCLC immunity. PEG‐rhG‐CSF increased CD3+ T and CD4+T cell proportions. PEG ‐rhG‐CSF increased TCR diversity and decreased clonality in peripheral blood. Change in TCR diversity were correlated with CD3+ T or CD4+ T changes. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 5, 2020 Category: Cancer & Oncology Authors: Jing Sun, Hua Bai, Zhijie Wang, Jianchun Duan, Jin Li, Ruimin Guo, Jie Wang Tags: ORIGINAL ARTICLE Source Type: research

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non ‐small cell lung cancer
ConclusionSABR of 60 Gy in eight fractions is feasible for ultracentral NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Dan Yang, Jianing Cui, Jun Zhao, Jing You, Rong Yu, Huiming Yu, Leilei Jiang, Dongming Li, Bo Xu, Anhui Shi Tags: ORIGINAL ARTICLE Source Type: research

MicroRNA ‐153‐3p regulates cell proliferation and cisplatin resistance via Nrf‐2 in esophageal squamous cell carcinoma
ConclusionMiR ‐153‐3p inhibits cell proliferation and confers cisplatin resistance by downregulating Nrf‐2 expression in Eca‐109 cells. Thus, miR‐153‐3p/Nrf‐2 may play an important role in conferring cisplatin resistance in ESCC. Nrf‐2 appears to be a promising therapeutic target for ESCC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Jing Zuo, Mei Zhao, Zhisong Fan, Bowei Liu, Yudong Wang, Yuehong Li, Ping Lv, Lingxiao Xing, Xianghong Zhang, Haitao Shen Tags: ORIGINAL ARTICLE Source Type: research

Totally mechanical linear stapled anastomosis for minimally invasive Ivor Lewis esophagectomy: Operative technique and short ‐term outcomes
ConclusionsThe results of our study suggest that this improved TM ‐STS technique is safe and effective for minimally invasive Ivor Lewis esophagectomy, and can be considered as one of the alternative procedure for patients with lower esophageal as well as Siewert types I/II gastroesophageal junction carcinoma. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Hui ‐Jiang Gao, Ju‐Wei Mu, Wei‐Min Pan, Malcolm Brock, Mao‐Long Wang, Bin Han, Kai Ma Tags: ORIGINAL ARTICLE Source Type: research

Issue Information
Thoracic Cancer, Volume 11, Issue 2, Page 203-204, February 2020. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 4, 2020 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor ‐related hematological adverse events
This study summarizes the manifestations of hematological irAEs and proposes preliminary recommendations for diagnosis and treatment.What this study adds• Much still remains unknown regarding hematological irAEs caused by checkpoint inhibitors. This study delineates the overview of hematological irAEs, and provides practical treatment suggestions, in particular addressing the issue of rechallenge. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Junling Zhuang, Jianhua Du, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Wei Qiu, Xiaoyan Si, Li Zhang, Yue Li, Xiaowei Liu, Hanping Wang, Daobin Zhou, Li Zhang Tags: CLINICAL GUIDELINE Source Type: research

Pre ‐embedded cervical circular stapled anastomosis in esophagectomy
ConclusionOur data revealed that pre ‐embedded cervical circular stapled anastomosis is an alternative for patients with good stomach length, which can decrease the occurrence rate of anastomotic fistula by full peripheral embedding of anastomotic stoma.Key points This new technique can significantly reduce the risk of anastomotic leakage. This study adds further details enabling a smooth pre ‐embedded procedure to be performed. (Source: Thoracic Cancer)
Source: Thoracic Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Jie Li, Bin Wang, Tao Liang, Nan ‐nan Guo, Ming Zhao Tags: ORIGINAL ARTICLE Source Type: research

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
AbstractThe increased use of targeted therapy and immune checkpoint inhibitors in cancers has brought new hope of survival to patients with advanced tumors. However, increasing numbers of immune ‐related adverse events (irAEs) of these medications have been reported, affecting almost all human organs including the eye. These adverse effects may affect the entire ocular region, including the eyelid, eye lashes, conjunctiva, cornea, uvea, retina and optic nerve, and have thus far been large ly ignored by patients and doctors. In this review, we summarize the characteristics of ocular diseases related to irAEs and advise on...
Source: Thoracic Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Xiaowei Liu, Zheng Wang, Chan Zhao, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiaoyan Si, Li Zhang, Yue Li, Mengzhao Wang, Meifen Zhang, Li Zhang Tags: CLINICAL GUIDELINE Source Type: research

Alteration of cell junctions during viral infection
Cell junctions serve as a protective barrier for cells and provide an important channel for information transmission between cells and the surrounding environment. Viruses are parasites that invade and commandeer components of host cells in order to survive and replicate, and they have evolved various mechanisms to alter cell junctions to facilitate viral infection. In this review, we examined the current state of knowledge on the action of viruses on host cell junctions. The existing evidence suggests that targeting the molecules involved in the virus ‐cell junction interaction can prevent the spread of viral diseases. ...
Source: Thoracic Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Dan Dong, Wei Xie, Min Liu Tags: MINI REVIEW Source Type: research

Salvage treatment of NSCLC recurrence after first ‐line chemotherapy failure: Iodine‐125 seed brachytherapy or microwave ablation?
This study was conducted to evaluate the clinical value of microwave ablation (MWA) and iodine‐125 brachytherapy, including overall survival (OS), disease free survival (DFS), local control, hospital stay, and health economics.MethodsThe data of 51 and 32 patients who were treated with MWA and brachytherapy was retrospectively analyzed. The number of lesions was limited up to two, with a diameter  
Source: Thoracic Cancer - January 29, 2020 Category: Cancer & Oncology Authors: Bin Liu, Yongzheng Wang, Shilin Tian, Yancu Hertzanu, Xiaogang Zhao, Yuliang Li Tags: ORIGINAL ARTICLE Source Type: research

Multiple variations in pulmonary veins during a thoracoscopic right lower lobectomy: A case report
A knowledge of pulmonary vein anatomy variants allows an appropriate preoperative radiological assessment and safe surgical management of vascular anomalies in patients undergoing major lung resections. In our case, multiple pulmonary vein variations were identified pre ‐ and intraoperatively in a patient undergoing thoracoscopic right lower lobectomy and included superior and common basal veins from the right lower lobe draining separately into the left atrium, middle lobe veins joining the superior segment right lower lobe vein and additional superior segment r ight lower lobe vein draining directly into the left atriu...
Source: Thoracic Cancer - January 28, 2020 Category: Cancer & Oncology Authors: Dario Amore, Dino Casazza, Umberto Caterino, Alessandro Saglia, Carlo Bergaminelli, Marcellino Cicalese, Pasquale Imitazione, Maria Rosaria Valentino, Roberta Civiletti, Carlo Curcio Tags: CASE REPORT Source Type: research

MicroRNA ‐based biomarkers for diagnosis of non‐small cell lung cancer (NSCLC)
ConclusionsIntegrating biomarkers across different body fluids would synergistically improve the early detection of NSCLC.Key points Lung cancer is a heterogeneous disease and develops from complex aberrations. Integrating sputum and plasma miRNAs has higher accuracy than when they are used alone (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 28, 2020 Category: Cancer & Oncology Authors: Jipei Liao, Jun Shen, Qixin Leng, Meng Qin, Min Zhan, Feng Jiang Tags: ORIGINAL ARTICLE Source Type: research

Unique metastasis ‐associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma
ConclusionsThis novel six ‐lncRNA signature had considerable prognostic value for prediction of relapse in LUAD patients.Key pointsSignificant findings of the studyThe unique metastasis ‐associated lncRNA signature was related to tumor metastasis and prognosis in LUAD patients.What this study addsThis signature had considerable prognostic value for prediction of relapse in LUAD patients. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 28, 2020 Category: Cancer & Oncology Authors: Xiaoshi Zhang, Jingyi Han, Lutao Du, Xiaoli Li, Jing Hao, Lili Wang, Guixi Zheng, Weili Duan, Yujiao Xie, Yinghui Zhao, Xin Zhang, Mingjin Zou, Chuanxin Wang Tags: ORIGINAL ARTICLE Source Type: research

Novel ProCore 25 ‐gauge needle for endobronchial ultrasound‐guided transbronchial needle aspiration reduces the puncture time and frequency, with comparable diagnostic rate for mediastinal and hilar lymphadenopathy
ConclusionThe ProCore 25 ‐gauge needle gained a similar diagnostic yield with less puncture time and frequency compared with the 22‐gauge needle. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 28, 2020 Category: Cancer & Oncology Authors: Li Yang, Ye Gu, Hai Wang, Dongmei Yu, Haiping Zhang, Hao Wang Tags: ORIGINAL ARTICLE Source Type: research

New data highlighting the efficacy and safety outcomes of third ‐generation EGFR‐TKI in NSCLC patients with rare EGFR mutations
Thoracic Cancer, EarlyView. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 28, 2020 Category: Cancer & Oncology Authors: Weisan Zhang, Fengtan Li, Wenyuan Gao Tags: EDITORIAL Source Type: research

Targeting the PI3K/Akt/mTOR pathway in non ‐small cell lung cancer (NSCLC)
The traditional classification of lung cancer into small cell lung cancer and non ‐small cell lung cancer (NSCLC) has been transformed with the increased understanding of the molecular alterations and genomic biomarkers that drive the development of lung cancer. Increased activation of the phosphatidylinositol 3‐kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway leads to numerous hallmarks of cancer and this pathway represents an attractive target for novel anticancer therapies. In NSCLC, the PI3K/Akt/mTOR pathway has been heavily implicated in both tumorigenesis and the progression of disease. A number o...
Source: Thoracic Cancer - January 27, 2020 Category: Cancer & Oncology Authors: Aaron C. Tan Tags: MINI REVIEW Source Type: research

Environmental pollutants damage airway epithelial cell cilia: Implications for the prevention of obstructive lung diseases
Mucociliary epithelium lining the upper and lower respiratory tract constitutes the first line of defense of the airway and lungs against inhaled pollutants and pathogens. The concerted beating of multiciliated cells drives mucociliary clearance. Abnormalities in both the structure and function of airway cilia have been implicated in obstructive lung diseases. Emerging evidence reveals a close correlation between lung diseases and environmental stimuli such as sulfur dioxide and tobacco particles. However, the underlying mechanism remains to be described. In this review, we emphasize the importance of airway cilia in mucoc...
Source: Thoracic Cancer - January 24, 2020 Category: Cancer & Oncology Authors: Yu Cao, Miao Chen, Dan Dong, Songbo Xie, Min Liu Tags: MINI REVIEW Source Type: research

Human papillomavirus infection maybe not associated with primary lung cancer in the Fujian population of China
BackgroundTo investigate whether human papillomavirus (HPV) infection is associated with primary lung cancer among the Fujian population.MethodsHPV infection was detected in 140 pairs of lung cancer tissues and matched paracancerous tissues by examining the 21 clinically relevant HPV types using a combination of viral highly conserved L1 region PCR amplification and specific probe reverse hybridization. Paired χ2 test was used to analyze differences in detection rates of HPV between lung cancer and paracancerous tissues. Differences in detection rates of HPV in lung cancer tissues were analyzed using χ2 test or the...
Source: Thoracic Cancer - January 23, 2020 Category: Cancer & Oncology Authors: Fei He, Weimin Xiong, Fanglin Yu, Rendong Xiao, Hailing Ye, Wenjun Li, Zhiqiang Liu, Zhijian Hu, Lin Cai Tags: ORIGINAL ARTICLE Source Type: research

Treatment outcome and clinical characteristics of HER2 mutated advanced non ‐small cell lung cancer patients in China
This study aimed to investigate the molecular and clinical patterns of HER2 mutations in advanced non‐small cell lung cancer (NSCLC), and compare the different outcomes between chemotherapy and HER2‐TKIs.MethodsAdvanced or recurrent non ‐small cell lung cancer patients with de novo HER2 mutations (N =  75) were included in this study. Molecular information, clinical features, and treatment outcomes were retrospectively collected from a web‐based patient registry and hospital chart review.ResultsBetween October 2012 and December 2018, 65 patients with in ‐frame insertion mutations, eight with point mutation...
Source: Thoracic Cancer - January 23, 2020 Category: Cancer & Oncology Authors: Fei Xu, Guangjian Yang, Haiyan Xu, Lu Yang, Weini Qiu, Yan Wang Tags: ORIGINAL ARTICLE Source Type: research

Long non ‐coding RNA XIST expedites lung adenocarcinoma progression through upregulating MDM2 expression via binding to miR‐363‐3p
ConclusionsXIST knockdown repressed proliferation, migration and invasion, and accelerated apoptosis of LAD cells by downregulating MDM2 expression via binding to miR ‐363‐3p.Key pointsSignificant findings of the study XIST and MDM2 were abnormally enhanced in LAD tissues and cells. Both downregulation of XIST and MDM2 repressed proliferation, migration and invasion, and boosted apoptosis of LAD cells in vitro. XIST bound to miR ‐363‐3p to regulate MDM2 expression in LAD cells.Downregulation of XIST impeded tumor growth on LAD cells in vivo.What this study addsThis study confirmed that XIST was a potential target f...
Source: Thoracic Cancer - January 22, 2020 Category: Cancer & Oncology Authors: Hao Rong, Bing Chen, Xing Wei, Jun Peng, Ke Ma, Song Duan, Jintao He Tags: ORIGINAL ARTICLE Source Type: research

Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD ‐1)/PD‐1 ligand (PD‐L1) inhibitors have been introduced to treat non‐small cell lung cancer (NSCLC) in recent years. Currently, PD‐1/PD‐L1 inhibitors are considered to have minor side effects and do not independently increase the risk of infection. However, they may cause immune‐relate d adverse events (irAEs) that require immunosuppressive therapy with corticosteroids and/or immunosuppressants, leading to opportunistic infections. Furthermore, there have been reports describing reactivation...
Source: Thoracic Cancer - January 22, 2020 Category: Cancer & Oncology Authors: Minya Lu, Li Zhang, Yue Li, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiaoyan Si, Yingchun Xu, Li Zhang Tags: CLINICAL GUIDELINE Source Type: research

Management of immune checkpoint inhibitor ‐related adverse events: A review of case reports
AbstractImmune checkpoint inhibitors represent a major breakthrough in cancer therapy. Immune ‐related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Management of irAEs is based on clinical experience because it is not easy to conduct prospective trials to evaluate the best treatment strategy. Using a combination of search terms in the PubMed an d Embase databases, we reviewed all cases in the English language citing toxicities associated with either pembrolizumab, nivolumab, ipilimumab, atezolizumab, tremelimumab, durvalumab, avelumab or any combination of these agents publis...
Source: Thoracic Cancer - January 22, 2020 Category: Cancer & Oncology Authors: Xiaoyan Si, Peng Song, Jun Ni, Mingyi Di, Chunxia He, Li Zhang, Xiaowei Liu, Yue Li, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xu Yang, Mengzhao Wang, Li Zhang Tags: INVITED REVIEW Source Type: research

Correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility: An updated meta ‐analysis
ConclusionBased on the present data, there was a significant correlation betweenMDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility. Individuals with G genotype may have an increased risk of developing esophageal cancer. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 22, 2020 Category: Cancer & Oncology Authors: Lele Yin, Guo Shen, Bin Zhu Tags: ORIGINAL ARTICLE Source Type: research

Overexpression of molecule GRP94 favors tumor progression in lung adenocarcinoma by interaction with regulatory T cells
ConclusionsOur study revealed that that GRP94 expression in lung AD favors tumor progression and predicts poor prognosis. The oncogenic role of GRP94 may involve inducing Treg infiltration by promoting the TGF ‐β signaling pathway.Key points GRP94 protein levels were elevated in lung AD tissues compared to normal lung tissues. The high expression ofGRP94 in lung AD favors tumor progression and predicts poor prognosis. The oncogenic role of the molecule GRP94 may involve the stimulation of Treg infiltrationvia promotion of the TGF ‐β signaling pathway. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 22, 2020 Category: Cancer & Oncology Authors: Xiao ‐Feng Duan, Ya‐Wei Xin Tags: ORIGINAL ARTICLE Source Type: research

A prospective study examining the impact of uniportal video ‐assisted thoracic surgery on the short‐term quality of life in patients with lung cancer
ConclusionThe advantages of uniportal VATS include a shorter hospital stay, more rapid recovery and superior cosmetic results compared to three ‐portal VATS. Additionally, uniportal VATS is superior to three‐portal thoracoscopic surgery in terms of the immediate postoperative short‐term QOL. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 22, 2020 Category: Cancer & Oncology Authors: Guang ‐wen Xu, Ming‐ran Xie, Han‐ran Wu, Ran Xiong, Cai‐wei Li, Shi‐bin Xu, Mei‐qing Xu, Tian Li Tags: ORIGINAL ARTICLE Source Type: research

Actin ‐like protein 8 promotes cell proliferation, colony‐formation, proangiogenesis, migration and invasion in lung adenocarcinoma cells
ConclusionThese results suggest that ACTL8 serves an oncogenic role in human LUAD cells, and that ACTL8 may represent a potential therapeutic target for LUAD.Key pointsOur results suggest that ACTL8 serves an oncogenic role in human LUAD cells, and that ACTL8 may represent a potential therapeutic target for LUAD. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 21, 2020 Category: Cancer & Oncology Authors: Shanwu Ma, Xiaowei Wang, Zhenrong Zhang, Deruo Liu Tags: ORIGINAL ARTICLE Source Type: research

Circular RNA 0007255 regulates the progression of breast cancer through miR ‐335‐5p/SIX2 axis
ConclusionCirc_0007255 functioned as a novel oncogene in the progression of BC by regulating miR ‐335‐5p/SIX2 axis, and might be a promising biomarker for BC treatment.Key pointsSignificant findings of the study: Levels of circ_0007255 and SIX2 were upregulated, but miR ‐335‐5p was diminished in BC tissues and cells. Circ_0007255 was an oncogene in BC development and exerted its function via miR‐335‐5p/SIX2 axis in BC. Tumor growth was reduced by circ_0007255 absence.What this study adds: Circ_0007255 functioned as a novel oncogene in the progression of BC by regulating miR ‐335‐5p/SIX2 axis, and might be a...
Source: Thoracic Cancer - January 21, 2020 Category: Cancer & Oncology Authors: Qianxin Jia, Lanlan Ye, Shangwen Xu, Hui Xiao, Siding Xu, Zhaoyin Shi, Jinsheng Li, Ziqian Chen Tags: ORIGINAL ARTICLE Source Type: research

LncRNA SNHG16 promotes non ‐small cell lung cancer development through regulating EphA2 expression by sponging miR‐520a‐3p
ConclusionSNHG16 promoted NSCLC development by regulating the miR ‐520a‐3p/EphA2 axis, suggesting novel insights for the pathogenesis of NSCLC and new potential therapeutic targets for the treatment of NSCLC.Key points Knockdown of SNHG16 inhibited NSCLC cell proliferation, migration, invasion and induced apoptosis in vitro as well as suppressed tumor growth in vivo. SNHG16 directly interacted with miR ‐520a‐3p. EphA2 was a target of miR‐520a‐3p. SNHG16 could regulate the expression of EphA2 by binding to miR‐520a‐3p. SNHG16 promoted NSCLC development by regulating the miR‐520a‐3p/EphA2 axis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 17, 2020 Category: Cancer & Oncology Authors: Lin Yu, Dewen Chen, Jie Song Tags: ORIGINAL ARTICLE Source Type: research

A case of middle mediastinal cavernous hemangioma
While cavernous hemangioma are frequently observed in various tissues and locations in the body, mediastinal cavernous hemangiomas (CHMs) are rare, particularly in the middle mediastinum. Here, we report a case of a middle CHM which was diagnosed and treated in our hospital. A male patient age 57  years was admitted with a mediastinal circular low‐density lesion. Preoperative examination was performed with a subsequent diagnosis of a mediastinal lesion. The lesion was resected and post‐operative histopathology suggested that it was a cavernous hemangioma. Post‐operative recovery was uneventful, and a follow‐...
Source: Thoracic Cancer - January 16, 2020 Category: Cancer & Oncology Authors: Xianqi Cai, Chunquan Liu, Yong Cui Tags: CASE REPORT Source Type: research

Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method
AbstractBackgroundThe aim of the study was to develop a deep learning (DL) algorithm to evaluate the pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer.MethodsA total of 302 breast cancer patients in this retrospective study were randomly divided into a training set (n =  244) and a validation set (n = 58). Tumor regions were manually delineated on each slice by two expert radiologists on enhanced T1 ‐weighted images. Pathological results were used as ground truth. Deep learning network contained five repetitions of convolution and max‐pooling layers and ended with three dense laye...
Source: Thoracic Cancer - January 16, 2020 Category: Cancer & Oncology Authors: Yu ‐Hong Qu, Hai‐Tao Zhu, Kun Cao, Xiao‐Ting Li, Meng Ye, Ying‐Shi Sun Tags: ORIGINAL ARTICLE Source Type: research

Histologic transformation of lung cancer during pembrolizumab therapy: A case report
Immune checkpoint inhibitors that block the programmed death 1/programmed death ligand 1 pathways are widely used to treat advanced lung cancers. There are seldom cases of histologic transformation reported after treatment with immunotherapy. Here, we report the case of a 69 ‐year‐old man with stage IV lung squamous cell carcinoma. He received pembrolizumab monotherapy and had a partial response. After 22 cycles of pembrolizumab, chest computed tomography (CT) showed a left hilar tumor, bilateral pleural effusion and lymphadenopathy. The cytology of pleural effusion and bronchoscopic biopsy of an intraluminal lesion re...
Source: Thoracic Cancer - January 16, 2020 Category: Cancer & Oncology Authors: Xiaoyan Si, Yan You, Xiaotong Zhang, Hanping Wang, Mengzhao Wang, Li Zhang Tags: CASE REPORT Source Type: research

Amyloid deposition in thymic extranodal marginal zone lymphoma of mucosa ‐associated lymphoid tissue in a patient with myasthenia gravis: A case report
Extranodal marginal zone lymphoma of mucosa ‐associated lymphoid tissue (MALT) in the thymus is a rare disease. Furthermore, amyloid deposition in thymic MALT lymphoma has not been previously described. Here, we report a case of a 35‐year‐old man with thymic MALT lymphoma with amyloid deposition and myasthenia gravis. Chest computed tom ography revealed an anterior mediastinal mass with internal cystic component and extensive calcification. Total thymectomy was performed and histopathologic findings were compatible with a diffuse amyloid deposition in extranodal marginal zone MALT lymphoma. The results indicate that ...
Source: Thoracic Cancer - January 15, 2020 Category: Cancer & Oncology Authors: Seulgi You, Joo S. Sun, Kyung J. Park, Young W. Koh Tags: CASE REPORT Source Type: research

Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?
BackgroundThis retrospective study compared the efficacy and side effect profile between postoperative adjuvant radiotherapy and chemoradiotherapy in stage II or stage III thoracic esophageal squamous cell carcinoma (TESCC) patients who underwent curative (R0) esophagectomy.MethodsA total of 272 TESCC patients who underwent radical esophagectomy from 2007 to 2016 were included in this retrospective analysis. All cases were pathologically confirmed with stage II or III disease and 148 patients received postoperative chemoradiotherapy (CRT), while the remaining 124 patients received postoperative radiotherapy (RT) alone.Resu...
Source: Thoracic Cancer - January 14, 2020 Category: Cancer & Oncology Authors: Bingwen Zou, Yan Tu, Duwen Liao, Yong Xu, Jin Wang, Meijuan Huang, Li Ren, Jiang Zhu, Youling Gong, Yongmei Liu, Lin Zhou, Xiaojuan Zhou, Feng Peng, You Lu Tags: ORIGINAL ARTICLE Source Type: research

Abivertinib in patients with T790M ‐positive advanced NSCLC and its subsequent treatment with osimertinib
ConclusionsAbivertinib is a unique novel third ‐generation EGFR TKI with good tolerance and efficacy in EGFR T790M(+) NSCLC patients. For patients with progressive disease after treatment with abivertinib, osimertinib could be an option for subsequent therapy but further studies are required.Key points Abivertinib is a novel third ‐generation EGFR TKI targeting theEGFR T790M mutation Abivertinib is well tolerated and efficacious in T790M ‐positive patients Abivertinib has a unique structure, efficacy, and resistance mechanism compared with osimertinib Osimertinib treatment after AC0010 showed a good response (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 14, 2020 Category: Cancer & Oncology Authors: Hanping Wang, Ruili Pan, Xiaotong Zhang, Xiaoyan Si, Mengzhao Wang, Li Zhang Tags: ORIGINAL ARTICLE Source Type: research

Detection of circulating tumor DNA from non ‐small cell lung cancer brain metastasis in cerebrospinal fluid samples
ConclusionSequencing of CSF ctDNA revealed specific mutation patterns in driver genes among patients with NSCLC and brain metastasis.Key pointsIn some small ‐sample studies, the importance of cerebrospinal fluid in guiding the treatment of cancerous brain lesions has been verified in that it may reflect genomic mutations of brain tumors relatively accurately.Cerebrospinal fluid is a new form of liquid biopsy that can be helpful in improving the management of patients with brain metastasis from non ‐small cell lung cancer by detecting genetic abnormalities specific to brain metastases. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Chunhua Ma, Xueling Yang, Wenge Xing, Haipeng Yu, Tongguo Si, Zhi Guo Tags: ORIGINAL ARTICLE Source Type: research

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non ‐small cell lung cancer
ConclusionsWith the sequential ALK inhibitors treatment, cancer cells accumulate new mutations in addition to mutations acquired previously. The identified compound mutation (I1171S  + G1269A) was found to be sensitive to ceritinib and brigatinib, and indeed the patient's tumor partially responded to ceritinib.Key points ALK compound mutation was found in a clinical sample that was resistant to lorlatinib after sequential ALK ‐tyrosine kinase inhibitor (TKI) treatment. Ceritinib and brigatinib are potential overcoming drugs against ALK I1171S + G1269A double mutation. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 13, 2020 Category: Cancer & Oncology Authors: Ken Takahashi, Yosuke Seto, Koutaroh Okada, Shinya Uematsu, Ken Uchibori, Mika Tsukahara, Tomoko Oh ‐hara, Naoya Fujita, Noriko Yanagitani, Makoto Nishio, Kenichi Okubo, Ryohei Katayama Tags: ORIGINAL ARTICLE Source Type: research

Salvage surgery using simultaneous clamshell thoracotomy with median sternotomy for mediastinal growing teratoma syndrome
This report describes the case of a 17 ‐year‐old man who developed mediastinal growing teratoma syndrome following two cycles of chemotherapy, after an initial diagnosis of primary mediastinal nonseminomatous germ cell tumor. The large, rapidly‐growing mediastinal tumor was completely resected in conjunction with right pneumonectom y, using simultaneous clamshell thoracotomy and median sternotomy. The salvage surgery with perioperative management involved in mediastinal growing teratoma syndrome is presented here.Key pointsSignificant findings of the study The diagnosis and surgical management are challenging for pa...
Source: Thoracic Cancer - January 11, 2020 Category: Cancer & Oncology Authors: Chieh ‐Ni Kao, Shah‐Hwa Chou, Chien‐Lin Huang, Chih‐Hung Lin, Hung‐Hsing Chiang, Jui‐Ying Lee, Hsien‐Pin Li, Po‐Chih Chang, Yu‐Wei Liu Tags: CASE REPORT Source Type: research

Hypoxia induced changes in miRNAs and their target mRNAs in extracellular vesicles of esophageal squamous cancer cells
ConclusionThis study, for the first time reveals changes in the expression of exosomal miRNAs in hypoxic ESCC cells and these findings will act as a resource to study the hypoxic tumor microenvironment and ESCC EVs. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 10, 2020 Category: Cancer & Oncology Authors: Fangyu Chen, Li Chu, Jie Li, Yu Shi, Bing Xu, Junjie Gu, Xijuan Yao, Meng Tian, Xi Yang, Xinchen Sun Tags: ORIGINAL ARTICLE Source Type: research

LncRNA NNT ‐AS1 promotes non‐small cell lung cancer progression through regulating miR‐22‐3p/YAP1 axis
ConclusionNNT ‐AS1 facilitated proliferation, migration, invasion and EMT of NSCLC cells by sponging miR‐22‐3p and regulating YAP1 expression, which might provide a potential biomarker and therapeutic target for NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 10, 2020 Category: Cancer & Oncology Authors: Wenlong He, Yeying Zhang, Shulan Xia Tags: ORIGINAL ARTICLE Source Type: research